Exclusive special offer and discount title banner vector image

ASIA-PACIFIC OPHTHALMIC DRUGS MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

Asia-Pacific Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/inflammation/allergies, Retinal Disorder, Other Indications) Market by Type (Prescription Drugs, Over-the-counter Drugs) Market by Dosage Form (Gels, Eye Solutions & Suspensions, Capsules & Tablets, Eye Drops, Ointments) Market by Therapeutic Class (Anti-glaucoma, Anti-infection, Anti-inflammatory, Anti-allergy, Other Therapeutic Classes) Market by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Other Distribution Channels) by Geography


MARKET OVERVIEW

The Asia-Pacific ophthalmic drugs market is expected to record a CAGR of 7.06% during the forecast period, 2023-2032, and is set to garner a revenue of $17897.47 million by 2032.

The ophthalmic drugs market growth in Asia-Pacific is attributed to the growing prevalence of age-related macular degeneration (AMD) and the rise of eye strain and related conditions due to surging digital device usage.

On the other hand, the Asia-Pacific ophthalmic drugs market growth is hindered by variability in healthcare reimbursement policies and eye care services.

Asia-Pacific Ophthalmic Drugs Market

To Know More About This Report, Request a Free Sample Copy

The Asia-Pacific ophthalmic drugs market growth analysis includes the assessment of China, Vietnam, Australia & New Zealand, Thailand, Japan, South Korea, Indonesia, India, and Rest of Asia-Pacific. China’s swiftly aging population and rising incidence of eye-related disorders have positioned the country as a major player in the global ophthalmic pharmaceutical industry. A key catalyst is the escalating prevalence of eye diseases, including glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and cataracts. The increasing occurrence of these conditions, attributed to China’s aging population and evolving lifestyle patterns, necessitates the utilization of ophthalmic drugs for effective treatment and management.

Further, the Chinese government’s endeavors to enhance healthcare infrastructure and foster research & development activities have made substantial contributions to the market’s expansion. Accordingly, initiatives aimed at raising awareness about eye health and extending healthcare services to rural areas have played a significant role in addressing ophthalmic disorders.

Whereas the ophthalmic drugs market in South Korea has experienced consistent expansion, primarily propelled by factors such as an aging demographic, a rising incidence of eye diseases, and an increasing awareness of eye health. The surge in screen time attributed to digitalization has heightened concerns about eye-related issues, contributing to a greater demand for ophthalmic drugs.

The Asia-Pacific ophthalmic drugs market segmentation includes dosage form, therapeutic class, type, indication, and distribution channel. The type segment includes over-the-counter drugs and prescription drugs.

Ophthalmic drugs prescribed by licensed eye care professionals are specifically formulated to address various eye-related conditions. These medications, available only with a valid prescription, cover a broad spectrum of eye ailments and necessitate careful evaluation, diagnosis, and monitoring by specialists like ophthalmologists or optometrists to ensure their safe and effective usage.

These prescription-based ophthalmic drugs are presented in diverse forms, such as eye drops, ointments, gels, and intraocular injections. Their design facilitates direct application to the eyes, delivering medication locally to affected tissues and minimizing systemic side effects.

For instance, anti-inflammatory drugs work to reduce inflammation in the eye resulting from conditions like uveitis, allergic conjunctivitis, or postoperative inflammation. Antibiotic eye drops or ointments are recommended for treating bacterial eye infections, including bacterial conjunctivitis or corneal ulcers. Viral eye infections, such as viral conjunctivitis and herpetic eye infections, are addressed with specific medications. Additionally, anti-glaucoma medications play a crucial role in lowering intraocular pressure for individuals with glaucoma, aiming to prevent or slow disease progression and preserve vision.

Ophthalmic drugs that are available without a prescription, commonly referred to as over-the-counter (OTC) drugs, can be directly bought from pharmacies, drugstores, or other retail outlets. Designed for self-administration, these medications target a range of common eye conditions or symptoms. In contrast to prescription-based ophthalmic drugs, OTC variants do not necessitate a prescription from a healthcare professional; consumers can simply purchase them directly from store shelves.

Some of the leading companies in the Asia-Pacific ophthalmic drugs market are Sun Pharmaceutical Industries Ltd, Santen Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc, etc.

Santen Pharmaceutical Co Ltd is engaged in the research, development, marketing, and manufacturing of medical devices and pharmaceutical products. The company operates production facilities in Suzhou, China and Shiga and Noto, Japan. Its product portfolio includes prescription ophthalmic products for bacterial conjunctivitis, retinal detachment, strabismus, hordeolum, amblyopia, diabetic retinopathy, etc. It is headquartered in Kita-ku, Osaka, Japan.

One of its key products, IKERVIS®, is used to treat adults with severe keratitis. It contains the active substance ciclosporin.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments Analyzed
Therapeutic Class, Dosage Form, Type, Indication, Distribution Channel
Countries AnalyzedChina, Vietnam, Australia & New Zealand, Thailand, Japan, South Korea, Indonesia, India, and Rest of Asia-Pacific
Companies AnalyzedAbbVie Inc, Accutome Inc, Bausch Health Companies Inc, Genentech Inc, Johnson & Johnson, Thea Pharma Inc, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
      1. IMPACT OF COVID-19 ON OPHTHALMIC DRUGS MARKET
    5. MAJOR MARKET FINDINGS
      1. EMERGING THERAPIES FOR DRY EYE SYNDROME
      2. GROWING DEMAND FOR COMBINATION THERAPIES
      3. INCREASING INVESTMENT IN RESEARCH & DEVELOPMENT
      4. SHIFT TOWARD OVER-THE-COUNTER (OTC) PRODUCTS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. AGING POPULATION’S SUSCEPTIBILITY TO AGE-RELATED EYE CONDITIONS
      2. ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
      3. RISING PREVALENCE OF EYE DISEASES AND DISORDERS
      4. FAVORABLE REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS
    2. KEY RESTRAINTS
      1. DELAY IN DRUG APPROVALS
      2. SIDE EFFECTS RELATED TO OPHTHALMIC DRUGS
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
    2. TECHNOLOGY SNAPSHOT
      1. BIOLOGICS
      2. CELL THERAPY
      3. GENE THERAPY
      4. DRUG DELIVERY
      5. SMALL MOLECULE
      6. OTHER TECHNOLOGIES
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. GROWTH PROSPECT MAPPING
    5. MARKET MATURITY ANALYSIS
    6. MARKET CONCENTRATION ANALYSIS
    7. KEY BUYING CRITERIA
    8. REGULATORY FRAMEWORK
  5. MARKET BY INDICATION
    1. DRY EYE
    2. GLAUCOMA
    3. INFECTION/INFLAMMATION/ALLERGIES
    4. RETINAL DISORDER
      1. WET AGE-RELATED MACULAR DEGENERATION
      2. DRY AGE-RELATED MACULAR DEGENERATION
      3. DIABETIC RETINOPATHY
      4. OTHER RETINAL DISORDERS
    5. OTHER INDICATIONS
  6. MARKET BY TYPE
    1. PRESCRIPTION DRUGS
    2. OVER-THE-COUNTER DRUGS
  7. MARKET BY DOSAGE FORM
    1. GELS
    2. EYE SOLUTIONS & SUSPENSIONS
    3. CAPSULES & TABLETS
    4. EYE DROPS
    5. OINTMENTS
  8. MARKET BY THERAPEUTIC CLASS
    1. ANTI-GLAUCOMA
    2. ANTI-INFECTION
    3. ANTI-INFLAMMATORY
    4. ANTI-ALLERGY
    5. OTHER THERAPEUTIC CLASSES
  9. MARKET BY DISTRIBUTION CHANNEL
    1. HOSPITAL PHARMACIES
    2. DRUG STORES
    3. ONLINE PHARMACIES
    4. OTHER DISTRIBUTION CHANNELS
  10. GEOGRAPHICAL ANALYSIS
    1. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET DRIVERS
      3. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET CHALLENGES
      4. KEY PLAYERS IN ASIA-PACIFIC OPHTHALMIC DRUGS MARKET
      5. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        5. INDONESIA
          1. INDONESIA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        6. THAILAND
          1. THAILAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        7. VIETNAM
          1. VIETNAM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        8. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        9. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  11. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
    2. COMPANY PROFILES
      1. ABBVIE INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      2. ACCUTOME INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      3. BAUSCH HEALTH COMPANIES INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      4. GENENTECH INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      5. JOHNSON & JOHNSON
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      6. THEA PHARMA INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      7. NOVARTIS AG
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      8. PFIZER INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      9. REGENERON PHARMACEUTICALS INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      10. SANTEN PHARMACEUTICAL CO LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      11. SUN PHARMACEUTICAL INDUSTRIES LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      12. TEVA PHARMACEUTICALS INDUSTRIES LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – OPHTHALMIC DRUGS

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 4: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 5: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 6: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 7: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 9: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 10: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 11: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 12: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 13: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 14: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 15: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 16: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 17: KEY PLAYERS OPERATING IN ASIA-PACIFIC OPHTHALMIC DRUGS MARKET

TABLE 18: LIST OF MERGERS & ACQUISITIONS

TABLE 19: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 20: LIST OF PARTNERSHIPS & AGREEMENTS

 

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING

FIGURE 4: MARKET MATURITY ANALYSIS

FIGURE 5: MARKET CONCENTRATION ANALYSIS

FIGURE 6: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY INDICATION, IN 2022

FIGURE 7: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2032 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2032 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INFECTION/INFLAMMATION/ALLERGIES, 2023-2032 (IN $ MILLION)

FIGURE 10: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2032 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY RETINAL DISORDER, IN 2022

FIGURE 12: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED MACULAR DEGENERATION, 2023-2032 (IN $ MILLION)

FIGURE 13: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED MACULAR DEGENERATION, 2023-2032 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY, 2023-2032 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL DISORDERS, 2023-2032 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER INDICATIONS, 2023-2032 (IN $ MILLION)

FIGURE 17: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022

FIGURE 18: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS, 2023-2032 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER DRUGS, 2023-2032 (IN $ MILLION)

FIGURE 20: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY DOSAGE FORM, IN 2022

FIGURE 21: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2032 (IN $ MILLION)

FIGURE 22: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS & SUSPENSIONS, 2023-2032 (IN $ MILLION)

FIGURE 23: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CAPSULES & TABLETS, 2023-2032 (IN $ MILLION)

FIGURE 24: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2032 (IN $ MILLION)

FIGURE 25: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2032 (IN $ MILLION)

FIGURE 26: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY THERAPEUTIC CLASS, IN 2022

FIGURE 27: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA, 2023-2032 (IN $ MILLION)

FIGURE 28: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION, 2023-2032 (IN $ MILLION)

FIGURE 29: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY, 2023-2032 (IN $ MILLION)

FIGURE 30: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY, 2023-2032 (IN $ MILLION)

FIGURE 31: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC CLASSES, 2023-2032 (IN $ MILLION)

FIGURE 32: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022

FIGURE 33: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES, 2023-2032 (IN $ MILLION)

FIGURE 34: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DRUG STORES, 2023-2032 (IN $ MILLION)

FIGURE 35: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES, 2023-2032 (IN $ MILLION)

FIGURE 36: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER DISTRIBUTION CHANNELS, 2023-2032 (IN $ MILLION)

FIGURE 37: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 38: CHINA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 39: JAPAN OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 40: INDIA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 41: SOUTH KOREA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 42: INDONESIA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 43: THAILAND OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 44: VIETNAM OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 45: AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 46: REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FAQ’s